CCL21 / SCYA21 Protein Price Inquiry ( Available Sizes )
CCL21 / SCYA21 Protein Product Information
A DNA sequence encoding the cyno CCL21 (Q8HYP5) (Met 1-Pro131) was expressed and purified.
CCL21 / SCYA21 Protein QC Testing
||> 94 % as determined by SDS-PAGE
CCL21 / SCYA21 protein
||< 1.0 EU per μg of the protein as determined by the LAL method
||Samples are stable for up to twelve months from date of receipt at -70℃
|Predicted N terminal:
The recombinant cyno CCL21 consists of 108 amino acids and has a calculated molecular mass of 12 kDa. It migrates as an 16 KDa band in SDS-PAGE under reducing conditions.
||Lyophilized from sterile PBS.
- Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
- Please contact us for any concerns or special requirements.
CCL21 / SCYA21 Protein Usage Guide
||Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
||A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
CCL21 / SCYA21 Protein Related Products & Topics
CCL21 / SCYA21 Protein Description
C-C motif chemokine 21, also known as 6Ckine, Beta-chemokine exodus-2. Secondary lymphoid-tissue chemokine, Small-inducible cytokine A21, CCL21 and SCYA21, is a secreted protein which belongs to the intercrine beta (chemokine CC) family. CCL21 / SCYA21 is highly expressed in high endothelial venules of lymph nodes, spleen and appendix. Intermediate levels of CCL21 / SCYA21 is found in small intestine, thyroid gland and trachea. Low level expression of CCL21 / SCYA21 in thymus, bone marrow, liver, and pancreas. It is also found in tonsil, fetal heart and fetal spleen. CCL21 / SCYA21 inhibits hemopoiesis and stimulates chemotaxis. CCL21 / SCYA21 shows preferential activity towards naive T-cells. It may play a role in mediating homing of lymphocytes to secondary lymphoid organs. CCL21 / SCYA21 has shown biological activities that include T cell, natural killer (NK) cell, and dendritic cell (DC) chemoattraction. Intratumoral administration of CCL21 / SCYA21 has potential as a neoadjuvant mmunotherapy for breast cancer.
- Christopherson KW. et al., 2001, Blood. 98 (13): 3562-8.
- Clark HF. et al., 2003, Genome Res. 13: 2265-2270.
- Ashour AE. et al., 2007, Cancer Biol Ther. 6 (8): 1206-10.
- Mumtaz M. et al., 2009, Oncol Rep. 21 (1): 153-8.